In brief: Cytopia; LCT; Rockeby
Thursday, 10 March, 2005
Cytopia (ASX:CYT) today filed an Investigational New Drug Application with the US Food and Drug Administration, seeking approval to test its cancer drug candidate CYT997 in the clinic.
Rockeby biomed (ASX:RBY) has announced the resignation of Dr John Warmington as the company's director of research and development. Warmington assume a consultancy role with the company as chief scientist. Dr David Capes will take up the position of vice president of research and development.
Xenotransplantation company Living Cell Technologies (ASX: LCT) has appointed Paris Brooke as general manager. Brooke was formerly policy and communication manager at AusBiotech.
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
